Transplant of cultured neuron-like differentiated chromaffin cells in a Parkinson's Disease patient. A preliminary report

Archives of Medical Research

Volumn 30, Issue 1, 1999, Pages 33-39

  Drucker Colín, René ^a,b   Verdugo Díaz, Leticia ^a   Morgado Valle, Consuelo ^a   Solís Maldonado, Gonzalo ^c   Ondarza, Rodolfo ^d   Boll, Catherine ^d   Miranda, Gabriela ^d   Wang, Gene Jack ^e   Volkow, Nora ^e  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^c PEMEX   (Mexico)

^d NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^e BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Chromaffin cells; Differentiation; Magnetic fields; Parkinson's disease; PET scan

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; LEVODOPA;

ADULT; ARTICLE; CASE REPORT; CAUDATE NUCLEUS; CELL DIFFERENTIATION; CELL TRANSPLANTATION; CHROMAFFIN CELL; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAGNETIC FIELD; MALE; NERVE CELL; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RATING SCALE; SCHOOL CHILD;

ADRENAL MEDULLA; ANTIPARKINSON AGENTS; BRAIN; CARBIDOPA; CARRIER PROTEINS; CAUDATE NUCLEUS; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; CHROMAFFIN CELLS; COMBINED MODALITY THERAPY; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GLUCOSE; HUMANS; LEVODOPA; MAGNETICS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; RECEPTORS, DOPAMINE; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROTOPIC; TREATMENT OUTCOME;

EID: 0033054315     PISSN: 01880128     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-0128(98)00007-4     Document Type: Article

References (47)

1. Björklund A., Dunnett S.B., Stenevi U., Lewis M.R., Iversen S.D. Reinnervation of the denervated striatum by substantia nigra transplants. functional consequences as revealed by pharmacological and sensoriomotor testing Brain Res. 199:1980;307.
2. Dunnett S.B., Björklund A., Stenevi U., Iversen S.D. Behavioral recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res. 215:1981;147.
3. Freed W.J., Perlow M.J., Karoum F., Seiger A., Olson L., Hoffer B.T., Wyatt R.J. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus. long term behavioral, biochemical and histochemical studies Ann Neurol. 8:1980;510.
4. Freed W.J., Poltorack M., Becker J.B. Intracerebral adrenal medulla grafts. a review Exp Neurol. 110:1990;139.
5. Fisher L.J., Gage F.H. Grafting in the mammalian central nervous system. Physiol Rev. 73:1993;583.
6. Hansen T.T., Bing G., Notter M.F.D., Kordower J.H., Fiandaca M.S., Gash D.M. Adrenal chromaffin cell as transplant in animal models of Parkinson's disease. J Electron Micros Tech. 12:1989;308.
7. Backlund E.O., Grenberg P.O., Hamberger B. Transplantation of adrenal medullary tissue to stratum in parkinsonism. J Neurosurg. 62:1985;169.
8. Madrazo I., Drucker-Colín R., Díaz V., Martínez-Mata J., Torres C., Becerril J.J. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med. 316:1987;831.
9. Drucker-Colín R., Madrazo I., Ostrosky-Solís F. Adrenal medullary tissue transplants in the caudate nucleus of Parkinson's patients. Prog Brain Res. 78:1988;567.
10. Allen G.S., Burns R.S., Tulipan N.B. Adrenal medullary transplantation into the caudate nucleus in Parkinson's disease. initial clinical results in 18 patients Arch Neurol. 46:1989;487.
11. Bakay R.A.E. Neurotransplantation. a clinical up-date Acta Neurochir. 58:1993;8.
12. Bakay R.A.E., Allen G.S., Apuzzo M. Preliminary report on adrenal medullary grafting from the American Association of Neurological Surgeons Graft Project. Dunnett S.B., Richards S.R. Neural Transplantation. From Molecular Basis to Clinical Application:1990;Elsevier, Amsterdam. 603.p.
13. Goetz C.G., Olanow C.W., Koller W.C. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease. multicenter study N Engl J Med. 320:1989;337.
14. López-Lozano J.J., Bravo G., Abscal J. Implants of human ventral mesencephalic neurons and perfused adrenal medullary tissue into the caudate nucleus of Parkinson's patients. preliminary results Soc Neurosci Abstr. 14:1988;5.
15. López-Lozano J.J., Bravo G., Abascal J., Brera B., Pascual M.L., Martínez R., de la Torre C., Moreno R. Clinical experience with cotransplantation of peripheral nerve and adrenal medulla in patients with Parkinson's disease. Transplant Int. 9:1996;485.
16. Porena M., Parziani S., Costantini E., Vespasiani G., Micali F. Autologous adrenal medullary transplant in Parkinson's disease. critical review of our results in 13 patients Neurourol Urodyn. 15:1996;195.
17. Watts R.L., Subramanian T., Freeman A., Goetz C.G., Penn R.D., Stebbins G.T., Kordower J.H., Bakay R.A. Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease. two-year follow-up study Exp Neurol. 147:1997;510.
18. Lindvall O. Transplantation into the human brain. present status and future possibilities J Neurol Neurosurg Psychiatr. 39:1989;54.
19. Lindvall O., Brundin P., Widner H., Rehnorona S., Gustavii B., Frackowiak R., Leenders K.L., Sawle G., Rothwell J., Marsden C.D., Björklund A. Grafts of fetal Dopamine neurons survive and improve motor function in Parkinson's disease. Science. 247:1990;574.
20. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., Zhang Y.B., Snyder J.A., Wells T.H., Ramig L.O., Thompson L., Mazziotta J.C., Huang S.C., Grafton S.T., Brooks D., Sawle G., Schroter G., Ansari A.A. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 327:1992;1549.
21. Defer G.L., Geny C., Ricolfi F., Fenelon G., Monfort J.C., Remy P., Villafane G., Jeny R., Samson Y., Keravel Y., Gaston A., Degos J.D., Peschanski M., Cesareo P., Nguyen J.P. Long term outcome of unilaterally transplanted Parkinsonian patients. I. Clinical approach. Brain. 119:1996;41.
22. Chung C.K., Kom H.J., Jeon B.S., Kim Y.S., Lee S.B., Han D.H. Unilateral fetal mesencephalic grafting in two patients with Parkinson's disease. short-term result after transplantation No Shinkei Geka. 24:1996;987.
23. Kordower J.H., Styren S., Clarke M., Dekosky S.T., Olanow C.W., Freeman T.B. Fetal grafting for Parkinson's disease. expression of immune markers in two patients with functional fetal nigral implants Cell Transplant. 6:1997;213.
24. Kordower J.H., Goetz C.G., Freeman T.B., Olanow C.W. Dopaminergic transplants in patients with Parkinson's disease. neuroanatomical correlates of clinical recovery Exp Neurol. 144:1997;41.
25. López-Lozano J.J., Bravo G., Brera B., Millan I., Dargallo J., Salmean J., Uria J., Insausti J. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus. 5-year follow up in 10 patients J Neurosurg. 86:1997;931.
26. Folkerth R.D., Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology. 46:1996;1219.
27. Boyer K.L., Bakay R.A.E. The history, theory and present status of brain transplantation. Functional Neurosurg. 6:1995;113.
28. Deacon T., Schumacher J., Dinsmore J., Thomas C., Palmer P., Kott S., Edge A., Penney D., Kassissieh S., Dempsey P., Isacson O. Histological evidence of fetal pig neural cell survival after transplantation with Parkinson's disease. Nat Med. 3:1997;350.
29. Asante-Korang A., Boyle G.J., Webber S.A., Miller S.A., Fricker F.J. Experience of FK506 immune suppression in pediatric heart transplantation. a study of long term adverse effects J Heart Lung Transplant. 15:1996;415.
30. Vescovi P., Savi A., Oppici A., Gennari P.V. Gingival hypertrophy due to ciclosporine. A review of the literature. Minerva Stomatol. 45:1996;523.
31. Olshan A.F., Mattison D.R., Zwanenburg T.S. Ciclosporine A. review of genotoxicity and potential for adverse human reproductive and developmental effects Mutat Res. 317:1994;163.
32. Unsicker K., Skaper S.D., Varon S. Neurotrophic and neurite-promoting factors. effects on early postnatal chromaffin cells from rat adrenal medulla Dev Brain Res. 17:1985;117.
33. Drucker-Colín R., Verdugo-Díaz L., Méndez M., Carrillo-Ruiz J., Morgado-Valle C., Hernández-Cruz A., Corkidi G. Comparison between low frequency magnetic field stimulation and nerve growth factor treatment of cultured chromaffin cells on neurite growth, noradrenaline release, excitable properties and grafting in nigro-striatal lesioned animals. Mol Cell Neurosci. 5:1994;485.
34. Doupe A.J., Landis StC Patterson P.H. Environmental influences in the development of neural crest derivates. glucocorticoids, growth factors and chromaffin cell plasticity J Neurosci. 5:1985;2119.
35. Notter M.F.D., Hansen J.T., Okawara S., Gash D.M. Rodent and primate adrenal medullary cells in vitro. phenotypic plasticity in response to coculture with C6 glioma cells or NGF Exp Brain Res. 76:1989;38.
36. Verdugo-Díaz L., Méndez M., Corkidi G., Drucker-Colín R. Phenotypic changes induced by replating of early post-natal rat chromaffin cells. Neurosci Lett. 183:1995;167.
37. 2+ channels in neurite growth of cultured chromaffin cells induced by Extremely Low Frequency (ELF) magnetic field stimulation. Cell Tissue Res. 291:1998;217.
38. Verdugo-Díaz L., Palomero-Rivero M., Drucker-Colín R. Differentiation of chromaffin cells by extremely low frequency magnetic fields changes release ratios of catecholamine type messenger. Bioelectro Bioenerg. 46:1998;297.
39. Tischler AS, Lee YC, Perlman RL, Costopoulos D, Bloom SR. Production of "ectopic" vasoactive intestinal peptide-like immunoreactivity in normal human chromaffin cell culture. Life Sci 1985;37:1881.
40. Herman M.A., Schulz C.A., Claude P. Effects of NGF and glucorticoid on NGF receptor immunolabeling of cultured rhesus adrenal chromaffin cells. Exp Cell Res. 200:1992;370.
41. Sternberger L.A., Hardy P.H., Cuculis J.J., Meyer H.G. The unlabeled antibody enzyme method immunohistochemistry. preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antiperoxidase) and its use in identification of Spirochetes J Histochem Cytochem. 18:1970;315.
42. 11C] raclopride binding in the human brain. J Nucl Med. 34:1993;609.
43. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley S.J., Schlyer D.J., Pappas N. A new PET ligand for the dopamine transporter. studies in the human brain J Nucl Med. 36:1995;2162.
44. Wang G.J., Volkow N.D., Hitzemann R.J., Pappas N., Pascani K., MacGregor R., Fowler J.S. Reproducibility of regional brain metabolic responses to lorazepam in normal human subjects. J Nucl Med. 37:1996;1609.
45. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J., Christman D.F. Graphical analysis of reversible binding from time activity measurements. J Cereb Blood Flow Metab. 10:1990;740.
46. Wu L.G., Saggan P. Presynaptic inhibition of elicited neurotransmitter release. TINS. 20:1997;204.
47. Flaris N., Tischler A.S. Substrate dependency of neurite outgrowth from adult human chromaffin cells. Inhibitory effects of human brain tissue. Lab Invest. 2:1990;493.